Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma

Treatment of metastatic malignant melanoma with vemurafenib during pregnancy.

Introduction The prognosis of stage IV malignant melanoma (MM) has for decades remained poor with median survival of 6 to 9 months. Half of MM tumors carry an activating mutation of the proto-oncogene, B-RAF. The BRAF-inhibitor vemurafenib increases overall and progression-free survival compared with treatment with the chemotherapeutic agent dacarbazine in MM patients with advanced disease. Vem...

Comparison of 5FU-base Chemoradiation with and without Eloxatin on Pathologic Complete Response in Neoadjuvant Chemoradiation of Rectal cancer

  Background and Objectives: To compare pathologic complete response (pCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection). Materials and Methods: Seventy-five consecutive patients with the diagnosis of advanced rectal adenocarcinoma were included. Two basic chemotherapy r...

Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience

OBJECTIVE : To assess the response rate of patients with rectal adenocarcinoma to neoadjuvant therapy and to identify the predictors of histological regression after neoadjuvant radiotherapy (RT) or concurrent chemoradiotherapy (CCRT). METHODS : This study recruited 64 patients. The patients had resectable cancer of the lower and the middle rectum (T3/T4 and/or N+) without distant metastasis ...

New therapeutical approaches for the treatment of malignant Melanoma

Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.

BACKGROUND Recent studies have indicated that response to chemotherapy and the prognostic impact of a pathologic complete response (pCR) after neoadjuvant chemotherapy differ among breast cancer subtypes. METHODS Women with Stage I to III breast cancer treated with anthracycline and taxane-based neoadjuvant chemotherapy (four cycles of docetaxel every 3 weeks followed by four cycles of FEC ev...